How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: Teclistamab (drug), Daratumumab (drug), Lenalidomide (drug), Dexamethasone (drug)
How long the study runs: Study runs about 132 months (dates as stated)
About the drug or intervention: Teclistamab — drug: Teclistamab will be administered as SC injection. · Daratumumab — drug: Daratumumab will be administered as SC injection. · Lenalidomide — drug: Lenalidomide will be administered orally. · Dexamethasone — drug: Dexamethasone will be administered either orally or intravenously (IV). · Talquetamab — drug: Talquetamab will be administered as SC injection.
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 18 Years and over
Who: All
Number of participants: 1,590
Started: 2022-10-25
Last checked: 2026-09

Plain English Summary

What is this study?

• Testing a new treatment for multiple myeloma
• Phase3 - 1,590 participants
• The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd)

Who can take part?

• Ages 18 Years and over
• Diagnosed with multiple myeloma

Where?

• Birmingham - University Hospitals Birmingham NHS Foundation Trust
• Blackpool - Blackpool Victoria Hospital
• Bristol - Bristol NHS Foundation Trust
• Cambridge - Addenbrooke's Hospital
• +5 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

Multiple Myeloma

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years and over
Who can join: All genders

Biomarkers mentioned

have a negative

What the study is looking for

✓Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria
✓Have an activity scale (ECOG) performance status score of 0 to 2
✓A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this...
✓A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the...

Who cannot take part

✗Had plasmapheresis within 28 days of randomization
✗Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization
✗Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients
✗Known contraindications to the use of daratumumab or lenalidomide per local prescribing information
✗Myeloma Frailty Index of \>=2 with the exception of participants who have a score of 2 based on age alone

See the full criteria

Inclusion Criteria: * Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria * Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment * Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 * A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment * A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment Exclusion Criteria: * Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams \[mg\] dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (\>=) 20 mg of dexamethasone within 14 days before randomization * Had plasmapheresis within 28 days of randomization * Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization * Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients * Known contraindications to the use of daratumumab or lenalidomide per local prescribing information * Myeloma Frailty Index of \>=2 with the exception of participants who have a score of 2 based on age alone